scholarly journals In Vivo Lymphatic Imaging of a Human Inflammatory Breast Cancer Model

2014 ◽  
Vol 5 (9) ◽  
pp. 774-783 ◽  
Author(s):  
Germaine D. Agollah ◽  
Grace Wu ◽  
Eva M. Sevick-Muraca ◽  
Sunkuk Kwon
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Lymphatic Imaging

scholarly journals In vivo albumin labeling and lymphatic imaging

2014 ◽  
Vol 112 (1) ◽  
pp. 208-213 ◽  
Author(s):  
Yu Wang ◽  
Lixin Lang ◽  
Peng Huang ◽  
Zhe Wang ◽  
Orit Jacobson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Optical Imaging ◽  
Evans Blue ◽  
Tumor Staging ◽  
Metastatic Breast ◽  
Fluorescence Signal ◽  
Blue Color ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Lymphatic Imaging

The ability to accurately and easily locate sentinel lymph nodes (LNs) with noninvasive imaging methods would assist in tumor staging and patient management. For this purpose, we developed a lymphatic imaging agent by mixing fluorine-18 aluminum fluoride-labeled NOTA (1,4,7-triazacyclononane-N,N',N''-triacetic acid)-conjugated truncated Evans blue (18F-AlF-NEB) and Evans blue (EB) dye. After local injection, both 18F-AlF-NEB and EB form complexes with endogenous albumin in the interstitial fluid and allow for visualizing the lymphatic system. Positron emission tomography (PET) and/or optical imaging of LNs was performed in three different animal models including a hind limb inflammation model, an orthotropic breast cancer model, and a metastatic breast cancer model. In all three models, the LNs can be distinguished clearly by the apparent blue color and strong fluorescence signal from EB as well as a high-intensity PET signal from 18F-AlF-NEB. The lymphatic vessels between the LNs can also be optically visualized. The easy preparation, excellent PET and optical imaging quality, and biosafety suggest that this combination of 18F-AlF-NEB and EB has great potential for clinical application to map sentinel LNs and provide intraoperative guidance.

Therapeutic monoclonal antibodies target phenotypically-differing human breast cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 13510-13510
Author(s):  
S. E. Hahn ◽  
L. A. da Cruz ◽  
D. Sayegh ◽  
A. Ferry ◽  
K. O’Reilly ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
In Vivo Studies ◽  
Tumor Growth Inhibition ◽  
Cancer Model ◽  
Human Breast ◽  
Breast Cancer Model ◽  
Cancer Tissues

13510 Background: CD44 (an adhesion molecule and stem cell antigen), CD59 (a complement-inhibitory molecule), MCSP (an adhesion and cell-cell interactions), and Trop-2 (EpCam a related signaling molecule) represent a group of biologically-significant cancer proteins acting through distinct mechanisms. We have described Abs with in vitro and in vivo cancer suppressive activity to this group of targets. However, their effectiveness depends on the phenotype of malignant cells; cell response should correlate with expression of its Ag, and tumor cells represent a heterogeneous group of non-synchronous cells. The present study describes the efficacy of those antibodies in breast cancer models and the prevalence of their antigen targets in a survey of human breast cancer tissues. Methods: In vivo activity of antibodies ARH460–16–2 (anti-CD44), AR36A36.11.1 (anti-CD59), AR11BD-2E11–2 (anti-MCSP), and AR47A6.4.2 (anti-Trop-2) in estrogen-dependent and hormone sensitive xenograft models of human breast cancer was examined. In addition, distribution of the antigens in breast cancer was determined by immunohistochemistry using tumor tissue arrays of breast cancer sections from distinct patients. Results: Treatment of an established breast cancer model with ARH460–16–2 resulted in 51% median tumor xenograft suppression (p<0.05), as well as increased survival in an MDA-MB-231 (breast cancer) grafted model. 63% of human breast cancer sections expressed the CD44 antigen. Treatment with anti-CD59 antibody AR36A36.11.1 resulted in 68% xenograft tumor suppression (p<0.005). AR47A6.4.2 anti-Trop-2 antibody bound to 100% of human breast cancer sections tested, and showed efficacy in the estrogen- dependent MCF-7 breast cancer model. Anti-MCSP antibody AR11BD-2E11–2 demonstrated 80% tumor growth inhibition (p<0.001), increased survival in an estrogen-dependent model of breast cancer, and was found to stain 62% of breast cancer tissues examined. Conclusions: The heterogeneity of breast cancer cell phenotypes in in vitro and in vivo studies and variable composite cellular antigen targets is the basis for the therapeutic use of multiple antibodies, each with independent mechanisms of action, and offers a rationale for combined antibody therapy in selected patients. [Table: see text]

Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer model

2014 ◽  
Vol 349 (2) ◽  
pp. 120-127 ◽  
Author(s):  
Lucia Borriello ◽  
Matthieu Montès ◽  
Yves Lepelletier ◽  
Bertrand Leforban ◽  
Wang-Qing Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Anti Tumor Activity

In vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic 1 Triple Negative Breast Cancer Model

2016 ◽  
Vol 16 (999) ◽  
pp. 1-1 ◽  
Author(s):  
Nuno Mendes ◽  
Francisco Tortosa ◽  
Andreia Valente ◽  
Fernanda Marques ◽  
António Matos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Cancer Model ◽  
Breast Cancer Model

In vivo optoacoustic monitoring of percutaneous laser ablation of tumors in a murine breast cancer model

2020 ◽  
Vol 45 (7) ◽  
pp. 2006
Author(s):  
Vijitha Periyasamy ◽  
Çağla Özsoy ◽  
Michael Reiss ◽  
Xosé Luís Deán-Ben ◽  
Daniel Razansky
Keyword(s):  
Breast Cancer ◽  
Laser Ablation ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Percutaneous Laser Ablation
Sign in / Sign up

Export Citation Format

Share Document